Research programme: monoclonal antibody therapies - Biocon/Vaccinex

Drug Profile

Research programme: monoclonal antibody therapies - Biocon/Vaccinex

Alternative Names: BVX-10; BVX-10 antibody; BVX10 MAb

Latest Information Update: 10 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocon; Vaccinex
  • Class Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 10 Oct 2016 Discontinued - Preclinical for Inflammation in India and USA (Parenteral)
  • 14 Oct 2011 Preclinical development is ongoing in India and the USA
  • 10 Apr 2007 Preclinical development is ongoing in Cancer and Inflammation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top